Want to see VVOS full AI Analyst Report?
Vivos Therapeutics (VVOS) Income Statement
Vivos Therapeutics Income Statement
Last quarter (Q2 2026), Vivos Therapeutics's total revenue was $5.15M, an increase of 34.90% from the same quarter last year. In Q2, Vivos Therapeutics's net income was $-5.48M. See Vivos Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| $ 17.44M | $ 15.03M | $ 13.80M | $ 16.02M | $ 16.89M | |
| $ 10.54M | $ 9.02M | $ 8.27M | $ 10.02M | $ 12.60M | |
| $ 30.44M | $ 20.19M | $ 25.57M | $ 35.05M | $ 32.08M | |
| Depreciation and Amortization | $ 1.31M | $ 581.00K | $ 621.00K | $ 669.00K | $ 733.00K |
| $ -19.92M | $ -10.55M | $ -12.96M | $ -23.18M | $ -19.54M | |
| $ -19.89M | $ -11.17M | $ -17.30M | $ -25.03M | $ -19.47M | |
| $ -1.34M | $ 35.00K | $ 3.71M | $ 1.19M | $ -817.00K | |
| $ -21.23M | $ -11.14M | $ -13.58M | $ -23.84M | $ -20.29M | |
| $ -21.23M | $ -11.14M | $ -13.58M | $ -23.84M | $ -20.29M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.06 | $ -2.22 | $ -11.14 | $ -25.90 | $ -23.89 |
| Diluted EPS | $ -2.06 | $ -2.22 | $ -11.14 | $ -25.90 | $ -23.89 |
| Weighted Average Shares Outstanding | 10.27M | 5.02M | 1.22M | 920.48K | 849.32K |
| Weighted Average Shares Outstanding (Diluted) | 10.27M | 5.02M | 1.22M | 920.48K | 849.32K |
Currency in USD
